To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: DG DISPATCH: APA: Treating Premenstrual Dysphoric Disorder URL: http://www.pslgroup.com/dg/1D316E.htm Doctor's Guide May 23, 2000
By Lara Pullen Special to DG News CHICAGO, IL -- May 23, 2000 -- Results from several clinical trials indicate that the selective serotonin reuptake inhibitors (SSRIs) have excellent efficacy and minimal side effects in the treatment of premenstrual dysphoric disorder (PMDD). Dr. Meir Steiner of McMaster University, Ontario, Canada reviewed several randomized, placebo-controlled trials studying the effects of SSRIs on the treatment of PMDD at the 2000 Annual Meeting of the American Psychiatric Association, Several SSRI's (fluoxetine, sertraline, paroxetine, clomipramine, fluvoxamine, and citalopram) have been tested for efficacy in the treatment of PMDD and it is difficult to distinguish between them in terms of efficacy. Clomipramine at 25-75 mg was found to be significantly more effective than placebo in reducing irritability as well as other symptoms associated with PMDD (n = 20). In a randomized, controlled trial (n = 65), paroxetine treatment resulted significant reduction in irritability, depression, anxiety, appetite, bloating, and breast tenderness. Another randomized, controlled trial demonstrated that sertraline treatment resulted in significantly decreased depressive symptoms, physical symptoms, and anger/irritability. In the case of clomipramine, paroxetine, and, perhaps, other SSRI's, three cycles of treatment seemed to be required for maximum efficacy. Dr. Steiner concluded by stating that, "Women who are being diagnosed with PMDD are not seeking treatment or help… so the onus is on us to identify them." --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.